PRNP D178N

How does codon 129 decide the phenotype?

The polymorphism at codon 129, methionine or valine, is common in the general population. What is important in D178N is the allele in cis, meaning on the same chromosome as the variant.

With 129 methionine in cis, the phenotype is usually fatal familial insomnia. With 129 valine in cis, it is usually genetic CJD. Reviews state this consistently, and the 2017 review puts it plainly: codon 129 on the mutant allele determines the phenotype.

The allele on the other chromosome modifies the course rather than the syndrome. In fatal familial insomnia, homozygotes have a shorter mean disease duration than heterozygotes, so two carriers in the same family with the same variant and the same cis allele are not in identical positions.

What are the figures for each phenotype?

For the 129V form, presenting as genetic CJD: literature onset averages 46 years, with a mean duration of 23 months and a range of 7 to 60 months. Dementia occurs in nearly all patients, and cognitive decline is the first symptom in 95 percent. In the UCSF centre’s own 129V patients, onset was 45 years with a standard deviation of 6 and a range of 37 to 52.

For the 129M form, fatal familial insomnia: duration averages about 13 to 15 months with a range of 4 to 40 months. Onset is typically in midlife, and a 2022 review describes duration as typically longer than a year. The syndrome combines progressive loss of normal sleep architecture, autonomic instability with hypertension, hyperhidrosis and pyrexia, and later cognitive impairment, ataxia and myoclonus. Fatal familial insomnia: more detail covers it in full.

The practical difference for a family is substantial. The 129V form looks like CJD and is likely to be recognised as such. The 129M form presents through sleep and autonomic symptoms that are commonly attributed to anxiety, insomnia or medication for months before anyone considers a prion disease.

What is known about penetrance?

D178N is in the high-penetrance group. The 2016 population-control analysis, comparing 16,025 prion disease cases against 60,706 ExAC exomes and 531,575 genotyped individuals, found allele frequencies for E200K, D178N, P102L and A117V consistent with up to 100 percent penetrance. A 2022 review describes D178N and P102L as nearly completely penetrant.

Those are the upper bounds compatible with population data, and the 2016 authors noted confidence intervals spanning more than an order of magnitude. No published figure gives an age-specific risk for an individual carrier, and that is the question families ask.

Is the 50 percent transmission figure settled for this variant?

It is the figure in current guidance, and D178N is the variant where it has been most directly challenged.

A 2025 study analysed 24 pedigrees, 65 nuclear families and 151 offspring across D178N and E200K. For D178N it reported 67.1 percent transmission with a 95 percent confidence interval of 56.3 to 77.9, with maternal transmission 67.5 percent and paternal 66.7 percent; only the maternal result reached significance, at p equal to 0.027 against 0.055 for paternal. The combined figure across both variants was 68.9 percent, interval 61.5 to 76.2. The authors proposed meiotic drive, gametic competition and embryonic selection as hypotheses, noting that prion protein is expressed in testicular tissue.

The limitations are stated by the authors and should travel with the figure. The design is retrospective; 18 percent of genotypes were inferred rather than tested, with a sensitivity analysis excluding those giving similar results; the paternal D178N analysis had 71 percent power; and D178N in this dataset is concentrated in the Basque population, where founder effects or population-specific modifiers could operate. They call for prospective validation across populations before counselling protocols change.

A family who has found this paper should hear the result and the caveat together, and the figure used in their own counselling is the one their genetics service applies. Family planning options covers the reproductive routes and the same caveat.

Why does the diagnostic assay matter so much here?

Because D178N associated with fatal familial insomnia is the most refractory subtype in CSF seeding assays, and the laboratory’s choice of substrate decides the answer.

In the 2026 Canadian comparison of 116 diagnostic CSF samples, the 13 FFI D178N cases gave 12 of 13 positive with a modified end-point assay using a deer mouse recombinant substrate, 4 of 13 with the standard hamster end-point assay, and 0 of 13 with second-generation IQ-CSF RT-QuIC. The single D178N case presenting as genetic CJD was detected by all three.

That split is the clinically actionable fact on this page. A negative IQ-CSF result in a suspected FFI case carries essentially no weight. Reviews add that periodic EEG complexes, CSF 14-3-3 and typical MRI changes are usually absent in FFI, and that RT-QuIC sensitivity appears to vary by population, with European cases often negative. What supports the diagnosis instead is polysomnography showing disrupted sleep architecture, FDG-PET showing thalamic hypometabolism, and the gene test.

The 2026 paper’s abstract reports 111 of 116 alongside 96.6 percent overall sensitivity, which corresponds to 112 of 116, so the headline figure deserves checking against the table before it is quoted.